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Abstract
Background: In the advent of increasing international collaborative research involving participants drawn from
populations with diverse cultural backgrounds, community engagement becomes very critical for the smooth
conduction of the research. The African Malaria Network Trust (AMANET) is a pan-African non-governmental
organization that sponsors and technically supports malaria vaccine trials in various African countries.
Case description: AMANET sponsored phase Ib or IIb clinical trials of several malaria vaccine candidates in various
Africa countries. In Burkina Faso, Mali and Tanzania trials of the merozoite surface protein 3 – in its Long Synthetic
Peptide configuration (MSP3 LSP) – were conducted. In Mali, the apical membrane antigen 1 (AMA1) was tested,
while a hybrid of glutamate rich protein (GLURP) and MSP3 (GMZ2) was tested in Gabon. AMANET recognizes the
importance of engaging with the communities from which trial participants are drawn, hence community
engagement was given priority in all project activities conducted in the various countries.
Discussion and evaluation: Existing local social systems were used to engage the communities from which
clinical trial participants were drawn. This article focuses on community engagement activities employed at various
AMANET-supported clinical trial sites in different countries, highlighting subtle differences in the approaches used.
The paper also gives some general pros and cons of community engagement.
Conclusions: Community engagement enables two-way sharing of accurate information and ideas between
researchers and researched communities, which helps to create an environment conducive to smooth research
activities with enhanced sense of research ownership by the communities.
Background
Conceptual framework of community engagement
Community engagement refers to the process of estab-
lishing two-way communication between researchers
and the researched communities. There are many ways
of engaging with communities due to different cultural,
traditional, religious, or socioeconomic factors prevailing
in the communities of interest. Efforts to ensure that
participating communities understand the purpose and
procedures of research could help to enhance mutual
trust and to create a sense of collective ownership of
research [1-4]. Exclusion of ordinary members of com-
munities from which participants are drawn, over and
above local beliefs and cultural practices, could create
conditions that are conducive to the generation of
misconceptions, rumours and suspicions about particu-
lar research projects, which could deter potential parti-
cipants from taking part in the research or could hinder
the progress of the research. The threat of negative
consequential effects of such social roadblocks or bottle-
necks on medical research and the potential involve-
ment of the media, some pressure groups or politicians,
imply that precautions should be taken to prevent or
preemptively act to minimize the potential occurrence
of such roadblocks or bottlenecks [5].
Such threats to the continuation of medical research
could outweigh approvals given by the responsible Minis-
tries of Health, ethics committees or regulatory authori-
t i e s ,a sw e l la si n f o r m e dc o n sent given by participants.
One real life example of such scenarios is the case of the
tenofovir multi-centre trials that were stopped in Cambo-
dia, Cameroon and Thailand due to pressure from
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against the Cambodian trial were lack of post-trial insur-
ance, inadequate care for participants who became HIV
positive during the trial and lack of community involve-
ment in the planning of the trial. As for the Cameroonian
trial, the complaints cited were inadequate informed con-
sent and education regarding prevention of HIV. In Thai-
land, groups opposed to the Thai tenofovir trial cited
ethical flaws in the trial design and lack of community
involvement. It could be argued that all the problems
encountered in these trials could have been prevented by
involving the communities right from the beginning,
instead of only engaging with other stakeholders such as
ethics committees and local collaborating researchers
who were probably considered to provide adequate com-
munity representation from the researchers’ point of
view and not from the participating communities’ point
of view. If their representation had been acceptable to the
participating communities, the communities would prob-
ably not have felt sidelined. Thus the social dimension of
health research requires engagement of the participating
communities at the grassroots level.
For epidemiological genetic studies, community sensi-
tization may be required to address potentially stigma-
tizing findings of the research. For instance, after several
genetic studies showed that the BRCA1 and BRCA2
mutations, which are associated with a predisposition to
breast cancer, and the APCI1307k allele associated with
predisposition to colorectal cancer were found at higher
rates in Ashkenazi Jews than the general population,
Jewish people became concerned about possibility of
stigmatization of Jews [7-9].
The increasing awareness of the need for sponsors and
researchers to be sensitive to non-biomedical social
aspects of health research and the increasingly cross-cul-
tural nature of health research have contributed towards
making health research more multi-disciplinary. For
instance, the International HapMap Consortium, made
up of partners from Canada, China, Japan, Nigeria and
the UK, set up groups of partners with responsibilities
to focus on scientific, analytical, legal, ethical and social
issues of the project [10]. The HapMap consortium
planned and budgeted for community engagement activ-
ities that were implemented before collection of samples
and continued after the samples were collected. The
activities included interviews, town meetings, focus
group discussions, community survey and setting up of
a Community Advisory Board (CAB) [11]. The CAB
continued to receive funding annually after the life span
of the consortium project in order to enable it to con-
vene community meetings aimed at updating and con-
sulting ordinary members of the communities.
It is, therefore, becoming increasingly imperative that
social, legal and ethical issues surrounding health
research be dealt with effectively and proactively in
order to prevent them from becoming serious obstacles
for the research. Community engagement helps not only
to identify the pertinent issues, but also enables the
communities concerned to contribute towards efforts to
address the challenges. Such a participatory approach
goes a long way in promoting mutual trust between
researchers and communities.
International guidelines on community engagement
Various international guidelines have also highlighted
the importance of community engagement over and
above individualized informed consent. For instance,
CIOMS guideline 4 states that researchers are obliged to
obtain informed consent from participants, and the
commentary on the guideline stresses that “Sponsors
and investigators should develop culturally appropriate
ways to communicate information that is necessary for
adherence to the standard required in the informed con-
sent process” [12]. This requirement is explicitly stated
in the 2006 supplement to the 2002 CIOMS guidelines
where commentary on guideline 4 states that “The opi-
nions of persons in a position equivalent to those whose
biological samples or records would be used in a study
offer a relevant point for determining whether such a
study would offend community norms of privacy and
autonomy. Such efforts are not the same as obtaining
permission from community leaders to undertake a
study...” [13].
The Nuffield Council on Bioethics (NCOB) 2002
report also stresses the importance of community invol-
vement or assent when conducting research in develop-
ing countries. Paragraph 6.19 of the NCOB 2002 report
states that “In some societies, it would be considered
culturally inappropriate for researchers to ask indivi-
duals to participate in research without consulting the
community or permission from community leaders”
[14]. Paragraph 6.20 goes on to warn that “....to seek
consent from an individual without seeking assent from
leader(s) of the community, or creating public accep-
tance of research, may be considered disrespectful and
may harm the relationships within that community and
between a community and researchers”.T h u s ,c o m m u -
nity engagement is emerging as a requirement for com-
munity-based research, in addition to ethical approval
and informed consent.
Responsibilities of sponsors and researchers regarding
community engagement
Sponsors and researchers should, therefore, make efforts
to enhance two-way communication with communities
to discuss issues that may be of concern to the
researched communities. Such communication could go
a long way in fostering partnerships between researchers
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collective ownership of the research. Partnerships could
minimize risks of potential misunderstandings that
could be fuelled by various factors such as rumours cir-
culating in the communities, incorrect media reports
that may crop up, and inadequate information and
explanations given to participants.
It has been acknowledged that social value of research
is as important as scientific validity [15]. The extra time
and expense spent on community engagement and con-
sultation processes help to add some value to the
research by creating an atmosphere of openness and pub-
lic trust because the processes involve (i) providing accu-
rate, complete and balanced information to ordinary
members of the community, (ii) giving ordinary people
an opportunity to express their views, and (iii) taking into
account and responding to communities’ views wherever
possible. Relying solely on approvals from local ethics
c o m m i t t e e sa n dr e g u l a t o r ya u t h o r i t i e sa n dv i e w sf r o m
high-level technical advisory bodies without any practical
efforts to interact directly with ordinary communities
may in the long run prove to be unsatisfactory to the
communities concerned and other stakeholders.
African Malaria Network Trust project activities in Africa
The African Malaria Network Trust (AMANET) [16] is
a pan-African non-governmental organization formed in
2002 from the African Malaria Vaccine Testing Network
(AMVTN), which was founded in 1995. In an effort to
promote conduction of health research in Africa that
meets international scientific and ethical standards,
AMANET takes a holistic approach that addresses infra-
structural, human and financial resource needs of Afri-
can research institutions. Consequently, AMANET
implements a range of activities across Africa that range
from capacity building of institutions and researchers to
sponsorship of clinical trials of malaria candidate vac-
cines. AMANET recognizes communities from which
research participants are drawn as critical stakeholders
who should be engaged and treated as ends in them-
selves and not as mere means to an end. This paper
outlines some examples of methods of engaging with
communities that have been used in various parts of
Africa where AMANET-sponsored clinical trials have
been conducted. Some potential pros and cons of com-
munity engagement are also discussed.
Case description: practical examples of community
engagement from Africa
Burkina Faso
In Burkina Faso, AMANET sponsored two phase Ib
trials of the merozoite surface protein 3 - in the long
synthetic peptide configuration (MSP3-LSP) malaria vac-
cine candidate in adults [17] and in children [18]. There
was no formal regulatory authority in Burkina Faso and
the Ministry of Heath had the mandate to grant
approval for clinical trials following favourable review
outcome by the national ethics committee. The clinical
trial site in Burkina Faso was at Balonghin, which is a
rural village about 45 km from the capital city, Ouaga-
dougou. The local study team had been doing research
with this community for at least eight years. The
researchers contributed substantially to the medical
infrastructure and health care publicly available to the
community, which enhanced community participation
and cooperation in the local research projects.
In preparation for the clinical trials, several meetings
with the communities were scheduled. The initial meet-
ings were exclusively between the senior investigators
and village chief with his elders. At these initial meetings,
information about objectives, methodology, potential
risks/benefits and importance of anticipated findings of
the intended clinical trials was provided. Figure 1 shows
some researchers with community leaders. Later, village
meetings were held in smaller units explaining details of
the proposed study by the research teams, taking time to
answer their questions. The fact that the main potential
benefit would be knowledge that could pave the way for
further late phase trials was thoroughly explained.
Repeated meetings were held in this manner until a sense
of reasonable understanding and acceptance of the pro-
posed study was reached. After the several meetings to
explain the study, the village chief finally gave permission
at a ceremonial meeting attended by villagers and other
stakeholders. The big ceremonial meeting was marked
with celebrations, food and traditional dances.
The experiences during the adult trial of MSP3-LSP
malaria vaccine in Balonghin demonstrated that com-
munity engagement can be taken further to help in the
random selection of participants. Briefly, the study was
designed to include 30 adult participants randomised to
receive either the study vaccine or control vaccine. In
order to have a group of eligible adults, all men aged
18-45 years were invited for screening. A total of 112
volunteers were found to be eligible. A local traditional
game was then employed at a gathering of the volun-
teers and other villagers to help transparently and ran-
domly select those who would undergo the screening
process for the study. The traditional game involved
putting 52 short and 60 long sticks in a drum, the short
sticks representing exclusion from the screening process
of the study, while the longer sticks represented inclu-
sion in the screening stage of the study. Each of the 112
volunteers had to blindly pick a stick from the drum
without attempting to feel the length of the stick and in
full view of cheering community members. The 60 villa-
gers who picked the long sticks became the volunteers
who proceeded to the screening stage aimed at selecting
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successfully used to randomly and fairly select indivi-
duals to be screened with everybody attending the com-
munity meeting understanding the basis of selection as
being equal chance for all the eligible candidates.
Mali
In Mali an AMANET-sponsored phase Ib trial of the
apical membrane antigen 1 (AMA1) malaria candidate
vaccine, which could potentially prevent Plasmodium
falciparum from invading red blood cells, was started in
adults in 2007 [19,20]. Another AMANET-sponsored
trial conducted in Mali was a phase IIb trial of the
MSP3-LSP malaria vaccine candidate in children under
the age of five years of age [21]; the MSP3-LSP vaccine
had been shown to be acceptably safe in the trial in
adults conducted in Burkina Faso. These clinical trials
were conducted by the Malaria Research and Training
Centre (MRTC), University of Bamako [22].
The experience of engaging with ordinary members of
communities in Mali was gained from two different clin-
ical trial sites; Bandiagara, a rural setting in the Dogon
region, and Sotuba, a peri-urban settlement on the out-
skirts of the capital city, Bamako. The experiences at
both field sites were essentially identical. Mali is gener-
ally a religious Muslim community with clearly struc-
tured administrative and traditional hierarchies. Both
structures had to be respected in the approach to the
potential study participants.
The first preparatory steps that had to be taken were
administrative; firstly the Ministry of Public Health had
to be officially informed, followed by the National Direc-
tor of health, then the Regional Director of health, then
the District Director of health, the District Prefect, and
finally the Mayor. After the administrative steps, the
process of community engagement was then initiated.
To enter the research community, prior appointments
h a dt ob em a d ew i t ht h ec h i e f .O nt h ed a yo ft h e
appointment, the investigator team was led by the head
of the local clinical site to the chief’s residence where
the village leaders, ordinary community members and
local government officials gathered.
After systematic introductions and welcoming remarks
by the village leaders and the chief, the research team
Figure 1 Picture showing the researchers with community leaders after a meeting in Burkina Faso.
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ing out the type of the study, aims of the study and
some information about collaboration between the local
site and AMANET as sponsor of the trial. The chief’s
translator was translating into the local vernacular lan-
guage. The community members and the chief asked
questions throughout the whole meeting. Notably, con-
trary to expectations of typical African traditional set-
tings, women were able to express their views freely.
Since the trials were phase Ib or IIb, it was explained
that even if the findings of the trials were positive, the
investigational products would not be ready after the
early phase trials but would need to undergo further
studies before they can be licensed for use.
Following the discussions and responses to questions
from the gathering, the chief spoke in support of the
intended clinical trial and gave permission for the trial
to be conducted. With the permission, research team
and the community leaders organized a meeting with
the ordinary members of the community that included
heads of families. Any questions were allowed and
answered by the research team. The engagement of the
ordinary members of the community was done before,
during and after the trial in order to ensure mainte-
nance of high level of community trust and commit-
ment. With an effective stepwise model of community
engagement in place, the MRTC has conducted a total
of ten phase I or II malaria vaccine trials with a follow-
up rate of at least 95%. The approach established has
also been used in other medical studies in Mali [2].
Gabon
In Gabon, AMANET sponsored two phase Ib trials of
GMZ2 malaria vaccine candidate, firstly in adults and
secondly in children aged one to five years [23]. The
GMZ2 vaccine is a promising candidate vaccine com-
posed of two components, the glutamate rich protein
(GLURP) and MSP3. The trial conducted in adults was
aimed at assessing the safety of the vaccine before test-
ing it in children. At the time of seeking approvals for
the first study, Gabon neither had a national ethical
committee nor a formal regulatory authority. A Regional
ethics Committee called CERIL provided the ethical
review and approval. After ethical approval was granted,
the protocol and the approval were then submitted to
the Ministry of Health, which played the role of the reg-
ulatory authority. Eventually, the ethical and regulatory
approvals were used as supporting documents for the
issuance of import permit to enable the importation of
the candidate vaccine into Gabon.
Having obtained the necessary approvals and import
permit, the researchers then arranged several commu-
nity entry meetings starting with the village chief, and
then village leaders. Upon permission being granted, the
researchers organized several community meetings with
the help of the community leaders. Announcements on
the local radios and flyers were used to advertise the
community meetings. Heads of families and their family
members attended the general community meetings. In
order to facilitate explanations to the members of the
community, the researchers organized drama groups
that conveyed information about the intended trial in
vernacular language. The local collaborating researchers
played a major role in packaging the information appro-
priately and in organizing the drama groups. During the
meetings the researchers invited people to consider par-
ticipating in the clinical trial if they met the inclusion
criteria, which were explained. After the community
engagement activities, which served to inform, sensitize
and invite potential participants, recruitment com-
menced at the trial site within the district hospital. The
informed consent process turned out to be very interac-
tive and effective because most of the volunteers had
attended the community meetings and were already
aware of the pertinent issues that needed to be
discussed.
Tanga, Tanzania
N I M RT a n g aC e n t r e[ 2 4 ]r e c e i v e df u n d i n gf r o mA M A -
NET in 2005 to prepare a site for malaria vaccine trial
in Korogwe district, north-eastern Tanzania [25]. Demo-
graphic surveillance system (DSS) was established
in 14 villages while passive case detection (PCD) of
malaria fevers by Community Owned Resource Persons
(CORPs) was done in four of the villages. In order to
ensure that community members had a sense of owner-
ship of the project activities, DSS workers and CORPs
were recruited from the villages where the project was
being conducted. Two malariometric surveys were con-
ducted each year; during short (November/December)
and long (May/June) rain seasons and these were pre-
ceded by village meetings to give details of the planned
activities and to seek for community assent. For the sur-
veys which were conducted after the baseline survey, the
community members and district authority were given
feedback of previous survey results and progress of DSS,
and PCD of fevers.
After completion of the preparatory project, a phase
1b MSP3-LSP malaria candidate vaccine trial sponsored
by AMANET was conducted in children under the aged
12 to 24 months [26]. The trial benefited from commu-
nity engagement activities that had been carried out
during the preparatory phase. Formal approvals were
obtained from the national ethics review committee and
the Tanzania Food and Drugs Authority (TFDA). Cour-
tesy calls were then made to the district administrative
officials. Regular contacts were made with the District
Medical Officer (DMO) updating him at each stage of
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tives from his office accompanied the team when con-
ducting some of the preparatory meetings.
At the village level, the first meeting was held with vil-
lage leaders to explain the intended trial and seek per-
mission to enter the village. The second meeting
involved village elders and heads of families in addition
to the village leaders. At this meeting information about
the objectives of the trial, potential risks, envisaged ben-
efits and procedures to be involved during the trial were
explained. Approval to convene a third meeting for the
villagers was sought and was granted. The third meeting
was then held in order to inform the ordinary members
of the community about the study. The aim, potential
risks, potential benefits and procedures of the study
were once again explained. Participants had an opportu-
nity to ask questions which were adequately answered
by the team of investigators. After the meeting, a copy
of information sheet was given to parents/guardians of
potential study participants to carry home and discuss
with their families and later on ask more questions if
any arose.
Following the various meetings, house-to-house sensi-
tization which involved parents and other family mem-
bers was done by the field workers. The field workers
visited every household with children in the target age
group to clarify issues about the study, which may have
arisen since the village meeting, answering questions
and clearing up misconceptions. The field workers were
also responsible for verifying that children whose names
were generated from the census list exist and to confirm
their reported age using the Maternal and Child Health
cards. In addition, the field workers identified other chil-
dren in the eligible age range within the same household
who might not have been registered during the census
survey. Lastly, they invited potential study participants
to attend screening sessions. The village had no local
clinic or dispensary infrastructure sufficient to support
the requirements of the trial, which was a randomized
and blinded study. Thus, the local community donated a
piece of land and the project constructed a modern
facility for the trial and handed it over to the commu-
nity for public health use as a local clinic after success-
ful completion of the trial. The established model of
community engagement was subsequently used during
Phase IIb RTS,S malaria vaccine trial in Korogwe,
Tanzania [27].
Bagamoyo, Tanzania
Having realised the important role that Ethics Review
Committees (ERCs) could play as a bridge between
researchers and researched communities, the Ifakara
Health Institute (IHI) ERC, using a sub-grant from
AMANET, started a two-way community engagement
programme aimed at conveying information about
health research ethics in general to the communities in
Bagamoyo, Tanzania. The Ifakara Health Institute [28]
was formerly named Ifakara Health Research & Devel-
opment Centre (IHRDC). In turn, the ERC and
researchers enhanced their understanding of community
concerns and perceptions of health research. Many clini-
cal trials and other studies funded by various organiza-
tions draw participants from the communities in
Bagamoyo [29,30]. For instance, Ifakara Health Institute
has been recruiting participants from communities in
Bagamoyo for the RTS,S multicentre trials being con-
ducted in many African countries [31,32].
The IHI ERC firstly obtained permission from the
community leaders to enter into their respective com-
munities. Thereafter, the ERC organized focus group
discussions with members of the communities in order
to discuss issues considered to be critical for the con-
duction of ethical research and to understand the views
or concerns of the ordinary members of the commu-
nities. Pamphlets that capture the important issues were
then developed and subsequently used in discussions
with the wider ordinary community members during
community meetings. The pamphlets were also made
freely available to the communities for possible further
discussions with family members in their homes with
the assistance of those who are literate. The pamphlets
basically explained the difference between research and
treatment, and the meaning of informed consent, poten-
tial risks and potential benefits in general terms. The
identified issues summarized in the pamphlets (Figure 2)
were thus used as a basis for further community engage-
ment activities. Since the pamphlets were in the verna-
cular language, Kiswahili, members of the communities
were able to discuss the issues among themselves, thus
facilitating sensitization of the communities through dis-
semination of the information. Figure 3 gives the issues
that are summarized in the pamphlets in English for the
benefit of the readers.
In addition, members of a Community Advisory Board
for IHI Bagamoyo Research Center were trained on
basic health research ethics (HRE). Field researchers
who work for Rufiji Demographic Surveillance System
were also trained on basic HRE. This approach by the
ERC of engaging communities to complement efforts
that may be made by researchers could go a long way in
encouraging participatory approach in health research
so as to ensure that participants and their communities
are treated as stakeholders who should be kept informed
about research conducted on them.
Discussion and evaluation
The experience gained in various African countries
shows that community leaders, who are the gatekeepers
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researchers to enter into the community and conduct
research. However, individual informed consent still had
to be obtained from participants recruited into particu-
lar studies. The community leaders and the researchers
explained that permission to enter the community was
not meant to substitute individual informed consent.
The permission given by the community leaders and
heads of families should therefore not be considered to
be the so called ‘community consent’,at e r mw h i c h
could imply that individual informed consent is not
necessary once permission has been granted by the
community leaders.
Although the approach used in the different countries
was basically the same (Figure 4), starting with adminis-
trative approval of the project, followed by permission
to enter into the communities and finally meeting with
t h eo r d i n a r ym e m b e r so ft h ec o m m u n i t i e s ,t h e r ew e r e
subtle procedural differences from site to site. Such dif-
ferences were due to cultural and traditional differences
in the social systems of the communities. However,
these experiences showed that smooth implementation
of any studies in these communities may not be possible
if such site-specific community-wide and structured
engagement is not followed. It is perhaps a distinctive
contextual feature among African communities that
mass mobilization with communal views on such issues
as research within their community remains important.
T h es i t u a t i o nm a yb ed i f f e r e n ti nu r b a n i z e da r e a s
where households tend to mind their own family affairs
following after the ‘westernized cultural model’. In such
urban settings, different approaches, which are feasible,
could be used. It may be difficult to define a specific tar-
get community in such situations, and the term ‘public
engagement’ may be more appropriate than ‘community
engagement’. For instance, researchers could explore
using the media (print, radio and TV) to disseminate
accurate information and to capture some views of the
public.
In general, the process of community engagement
basically shows respect for the communities that partici-
pate in research. Planning, setting aside time and
budgeting for community engagement activities demon-
strates that the communities are being treated as critical
Figure 2 Pamphlet and picture of community engagement activity by IHI IRB.
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for academic or commercial purposes. As outlined in
Figure 5, community engagement helps to enhance
comprehension of the research by the communities on
one hand, and of community views and concerns by the
researchers on the other. For instance, in Burkina Faso a
local game that the community was familiar with was
used to randomly select research participants. Thus
although certain scientific jargon such as ‘random
selection’ may not have equivalent terms in the vernacu-
lar language, the jargon could be made understandable
if appropriate concepts or practices that may be avail-
able locally are used to elaborate the scientific proce-
dures or jargon.
Some studies have shown that prospective participants
in developing countries may need time to consult with
their spouses or relatives before making a decision
whether or not to participate in a research project
Figure 3 Translation of the information on the pamphlet used by Ifakara Health Institute IRB.
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way in facilitating such internal family consultations
since communities of the prospective participants may
already be aware of the intended research projects.
Overall, the community engagement process strengthens
the relationship and trust between researchers and the
communities.
However, community engagement also has some
potential cons that should be watched out for and
addressed whenever they arise. Firstly, although a time-
frame may be put in place upfront, the process may
take longer than planned due to the step-wise proce-
dure, which is usually beyond the control of the
researchers but is dependent on the existing local socie-
tal systems. Secondly, due to peer pressure, some indivi-
duals may feel obliged to take part in the proposed
studies lest they are perceived as being against the
wishes of the whole community, and may be treated as
outcasts. Thirdly, the process of community engagement
may raise the expectations of the community to levels
beyond what the proposed study may be capable of
tackling.
Conclusions
T h ec a s ee x a m p l e sf r o mA f r i c as h o wt h a ti n v o l v i n g
communities from which research participants are
drawn adds some social value to the research over and
above the potential scientific benefits. Even if early
phase trials do not yield products that may be used
soon after completion of the trials, the communities
appreciated the importance of such trials because the
researchers made concerted efforts to explain and
answer questions some of which may seem basic and
trivial from a researchers point of view. The engagement
with the communities created trust between the
researchers and the communities, making the ordinary
members of the communities feel a sense of ownership
of the research.
Although there could be potential challenges such as
lengthy processes and expectations that may be too high
to meet, the overall potential benefits of engaging with
target communities outweigh the challenges. Indeed,
community engagement is an appropriate platform to
address such challenges if they arise. The ordinary
members of the communities do not necessarily have to
understand the science behind the clinical trials, but
need to understand such simple and straightforward
issues as (i) the difference between research and health
care delivery, (ii) purpose of doing the trial, (iii) research
procedures involved such as number of injections and
collection of blood samples, (iv) number of scheduled
visits, (v) the known potential risks and (vi) the potential
benefits such as knowledge about the safety and efficacy
of the investigational product.
Figure 4 General steps in community engagement at the various sites.
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